After a year of change at Sanofi, R&D chief Houman Ashrafian is leading the French drugmaker’s deepened focus on new medicines. We’ll speak with him about how more big pharma companies are focusing their bets, Sanofi’s priorities for the future and how the company believes AI can help it find new treatments.

Cell and gene therapies hold life-saving potential, but their complex manufacturing processes create significant barriers to scalability and widespread patient access. Solving these bottlenecks is critical to the industry’s viability. Hear how Ori Biotech is delivering innovations to help expand treatment access and scale the clinical and commercial impact of these therapies.

Last year, the FDA approved the first-ever therapy using CRISPR gene editing — a milestone made possible by the work of Nobel laureate Jennifer Doudna. The gene editing pioneer will share her reflections on the last decade of CRISPR and the challenges and promise of gene editing technology.

Obstructive Sleep Apnea (OSA) affects over 80 million people in the U.S., yet it remains one of the most underdiagnosed and undertreated chronic diseases. Apnimed is trying to change that. Hear CEO Larry Miller discuss Apnimed’s pioneering efforts in developing a first-in-class oral therapy designed to address the neuromuscular root causes of OSA.

Rapport was the third neuroscience drug developer to go public in 2024. CEO Abe Ceesay will give a behind-the-scenes look at how and why the company decided to go public when it did and why now is such an opportune time to tackle brain diseases.

Artificial Intelligence is revolutionizing every facet of the life sciences industry, propelling leading companies to unprecedented levels of efficiency, innovation, and patient outcomes. Industry leaders will explore two critical dimensions of AI transformation in pharma: strategic dealmaking and real-world applications. We’ll share insights on how AI-driven partnerships are reshaping the landscape while examining concrete applications that are delivering measurable value across the entire value chain.

Every year, a lion’s share of research spending and venture capital goes to cancer. But within the field itself, priorities are always shifting. What mechanism and treatment approaches will take center stage in 2025 and how will research and investment dollars follow? 

Altos Labs launched in 2022 with $3 billion and an audacious goal of rejuvenating cells to fight aging. CEO Hal Barron will give a glimpse into what Altos has been up to and why he left his role as GSK's chief scientist to lead Altos in the belief that the time for longevity has, finally, arrived.

We’re sitting down with legendary figures in research and development to reflect on the past few years in the field: What sure things ended up not paying off? What sleeper ideas ended up defining a field? And what comes next?

Join Endpoints reporters and editors to wrap up the past two days of sessions. They’ll share their main takeaways from the conversations and from JPM and make their predictions for the year ahead.